Sensitivity and Specificity of Strategies to Identify Patients with Haemostasis Abnormalities Leading to an Increased Risk of Bleeding Before Scheduled Intervention: the Hemorisk Study.

Blood Coagulation Disorders Hemorrhage Questionnaire Surgical Procedures Women

Journal

Journal of thrombosis and haemostasis : JTH
ISSN: 1538-7836
Titre abrégé: J Thromb Haemost
Pays: England
ID NLM: 101170508

Informations de publication

Date de publication:
09 Aug 2024
Historique:
received: 29 11 2023
revised: 17 07 2024
accepted: 28 07 2024
medline: 12 8 2024
pubmed: 12 8 2024
entrez: 11 8 2024
Statut: aheadofprint

Résumé

Preoperative identification of patients with haemostasis abnormalities leading to an increased bleeding risk was based on routine haemostasis tests: prothrombin time (PT), activated prothrombin time (aPTT), and platelet count. Because of their low predictive performance, guidelines recommend replacing them with structured bleeding risk questionnaires, but none is validated in this population. To assess the diagnostic accuracy of 3 strategies, performed at the pre-anaesthesia visit before scheduled interventions, to identify patients with haemostasis abnormalities leading to an increased bleeding risk PATIENTS AND METHODS: Multicenter study in 7 French academic hospitals, involving patients scheduled for surgical intervention, without antiplatelet/anticoagulant treatment. The 3 strategies consisted of 1-a structured screening questionnaire; 2-PT, aPTT, and platelet count ordered in selected patients; 3-systematic PT, aPTT, and platelet count. The reference standard comprised von Willebrand factor activity/antigen, factors VIII, IX, and XI, platelet-function analyser, and, when required, FII, FV, FX, and FVII and haemostasis consultation. Eighteen (1.2%) of 1484 patients had a haemostasis abnormality leading to an increased bleeding risk according to reference standard. In the overall cohort, sensitivity of the questionnaire-based strategy was 50% (95%CI, 26-74; specificity 87% (95%CI, 85-88); sensitivity was 0 (95%CI, 0-41) in men vs 82% (95%CI, 48- 98) in women. For selective routine tests, sensitivity was 33% (95%CI, 13-59) and specificity 97% (95% CI, 96-98). Corresponding values for systematic routine tests were 44% (95%CI, 22-69) and 93% (95%CI, 91-94). Sensitivity was low for all 3 strategies investigated. The structured screening questionnaire had clinically acceptable diagnostic accuracy only in women.

Sections du résumé

BACKGROUND BACKGROUND
Preoperative identification of patients with haemostasis abnormalities leading to an increased bleeding risk was based on routine haemostasis tests: prothrombin time (PT), activated prothrombin time (aPTT), and platelet count. Because of their low predictive performance, guidelines recommend replacing them with structured bleeding risk questionnaires, but none is validated in this population.
OBJECTIVES OBJECTIVE
To assess the diagnostic accuracy of 3 strategies, performed at the pre-anaesthesia visit before scheduled interventions, to identify patients with haemostasis abnormalities leading to an increased bleeding risk PATIENTS AND METHODS: Multicenter study in 7 French academic hospitals, involving patients scheduled for surgical intervention, without antiplatelet/anticoagulant treatment. The 3 strategies consisted of 1-a structured screening questionnaire; 2-PT, aPTT, and platelet count ordered in selected patients; 3-systematic PT, aPTT, and platelet count. The reference standard comprised von Willebrand factor activity/antigen, factors VIII, IX, and XI, platelet-function analyser, and, when required, FII, FV, FX, and FVII and haemostasis consultation.
RESULTS RESULTS
Eighteen (1.2%) of 1484 patients had a haemostasis abnormality leading to an increased bleeding risk according to reference standard. In the overall cohort, sensitivity of the questionnaire-based strategy was 50% (95%CI, 26-74; specificity 87% (95%CI, 85-88); sensitivity was 0 (95%CI, 0-41) in men vs 82% (95%CI, 48- 98) in women. For selective routine tests, sensitivity was 33% (95%CI, 13-59) and specificity 97% (95% CI, 96-98). Corresponding values for systematic routine tests were 44% (95%CI, 22-69) and 93% (95%CI, 91-94).
CONCLUSIONS CONCLUSIONS
Sensitivity was low for all 3 strategies investigated. The structured screening questionnaire had clinically acceptable diagnostic accuracy only in women.

Identifiants

pubmed: 39128655
pii: S1538-7836(24)00444-6
doi: 10.1016/j.jtha.2024.07.024
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Informations de copyright

Copyright © 2024 International Society on Thrombosis and Haemostasis. Published by Elsevier Inc. All rights reserved.

Auteurs

Nadine Ajzenberg (N)

Department of biological haematology, Assistance Publique-Hôpitaux de Pairs (AP-HP), Hôpital Bichat-Claude Bernard, F-75018 Paris, France; University Paris Cité and Université Sorbonne Paris Nord, INSERM, LVTS, F-75018, Paris, France. Electronic address: nadine.ajzenberg@aphp.fr.

Dan Longrois (D)

APHP, CHU Bichat-Claude Bernard, DMU PARABOL Paris, France.

Dorothée Faille Pharma D (DF)

Department of biological haematology, Assistance Publique-Hôpitaux de Pairs (AP-HP), Hôpital Bichat-Claude Bernard, F-75018 Paris, France; University Paris Cité and Université Sorbonne Paris Nord, INSERM, LVTS, F-75018, Paris, France.

Christian de Tymowski (C)

APHP, CHU Bichat-Claude Bernard, DMU PARABOL Paris, France; INSERM UMR 1149, Immunorecepteur et Immunopathologie Rénale, CHU Bichat-Claude Bernard, Paris, France.

Emmanuelle De Raucourt (E)

Department of biological haematology, Hôpital Beaujon, AP-HP, Clichy, France.

Larbi Boudaoud (L)

Department of biological haematology, Hôpital Beaujon, AP-HP, Clichy, France.

Stéphanie Sigaut (S)

Department of anaesthesia and Intensive Care, Hôpital Beaujon, AP-HP, Clichy, France.

Isabelle Martin-Toutain (I)

Department of biological haematology, Hôpital Pitié-Salpétrière, AP-HP, F-75013 Paris.

Mathieu Raux (M)

Department of anaesthesia and intensive care, Pitié-Salpêtrière Charles Foix Hospital, AP-HP, 75013 Paris, France.

Dominique Helley (D)

Department of biological haematology, Hôpital européen Georges Pompidou, AP-HP, F-75015 Paris, France; Universty Paris Cité, Inserm, PARCC, F-75015 Paris, France.

Julien Josserand (J)

Department of anaesthesia and Intensive Care, Hôpital européen Georges Pompidou, AP-HP, F-75015 Paris, France.

Claire Flaujac (C)

Department of biological haematology, Hôpital Cochin, AP-HP, F-75014 Paris.

Jérome Duchemin (J)

Department of biological haematology, Hôpital Cochin, AP-HP, F-75014 Paris.

Charles Marc Samama (CM)

GHU APHP Department of Anaesthesia and Intensive Care, Hôpital Cochin, AP-HP, F-75014 Paris, France. Centre - Université Paris Cité France.

Isabelle Gouin-Thibault (I)

Department of biological haematology, Hôpital Pontchaillou, Univ Rennes, IRSET, Inserm 1085, Rennes, France.

Hélène Beloeil (H)

Department of anaesthesia and Intensive Care, Univ Rennes, CHU Rennes, Inserm, CIC-1414, COSS 1242, Rennes, France.

Edith Peynaud-Debayle (E)

Department of biological haematology, Hôpital Louis Mourier, AP-HP, Colombes, France.

Hawa Keita-Meyer (H)

Department of anaesthesia, Hôpital Louis Mourier, AP-HP, Colombes, France. Department of anaesthesia and Intensive Care, Hôpital Necker, AP-HP, Paris, France.

Marie-Charlotte Bourrienne (MC)

Department of biological haematology, Assistance Publique-Hôpitaux de Pairs (AP-HP), Hôpital Bichat-Claude Bernard, F-75018 Paris, France; University Paris Cité and Université Sorbonne Paris Nord, INSERM, LVTS, F-75018, Paris, France.

Caroline Quintin (C)

AP-HP, Groupe Hospitalier Universitaire APHP-Nord Université Paris Cité, Research Clinic, Epidemiology, Biostatistic Department, Bichat Hospital, DMU PRISME, Paris, France.

Catherine Paugam-Burtz (C)

Department of anaesthesia and Intensive Care, Hôpital Beaujon, AP-HP, Clichy, France.

Nadia Rosencher (N)

GHU APHP Department of Anaesthesia and Intensive Care, Hôpital Cochin, AP-HP, F-75014 Paris, France. Centre - Université Paris Cité France.

Jean-Baptiste Valentin (JB)

Department of biological haematology haemostasis, CHRU de Tours - Hôpital Trousseau, Tours France.

Caroline Giboin (C)

AP-HP, INSERM, Hôpital Pitié Salpêtrière, Centre de Pharmaco-épidémiologie (Cephepi), CIC-1901, F75013, Paris, France.

Florence Tubach (F)

AP-HP, Groupe Hospitalier Universitaire APHP-Nord Université Paris Cité, Research Clinic, Epidemiology, Biostatistic Department, Bichat Hospital, DMU PRISME, Paris, France; Sorbonne University, INSERM, Institut Pierre Louis d'Epidémiologie et de Santé Publique, AP-HP, Hôpital Pitié Salpêtrière, Département de Santé Publique, Centre de Pharmacoépidémiologie (Cephepi), CIC-1901, F75013, Paris, France.

Classifications MeSH